PubRank

James C Yang

Author PubWeight™ 267.30‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002 19.77
2 Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004 17.61
3 Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006 16.96
4 Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005 12.88
5 Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003 10.71
6 Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008 10.13
7 Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008 9.82
8 Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005 9.72
9 Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009 9.24
10 Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011 9.19
11 Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010 9.13
12 Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011 9.03
13 B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2011 8.26
14 Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006 7.40
15 A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006 7.09
16 Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014 6.88
17 Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007 5.51
18 Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005 5.36
19 Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013 4.80
20 CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012 4.56
21 A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002 4.31
22 Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002 4.15
23 Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005 3.73
24 PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest 2014 3.54
25 T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2010 3.29
26 Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010 3.06
27 Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 2004 2.84
28 Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005 2.84
29 Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol 2004 2.22
30 Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008 2.15
31 Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother 2003 2.10
32 CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010 1.92
33 Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 2009 1.78
34 Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 2004 1.77
35 High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008 1.74
36 Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 2013 1.67
37 Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006 1.66
38 Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 2002 1.65
39 Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother 2003 1.55
40 Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor. Blood 2011 1.54
41 Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol 2013 1.50
42 Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res 2003 1.46
43 Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother 2010 1.35
44 Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother 2004 1.34
45 αβ T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities. Immunity 2011 1.33
46 Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res 2010 1.31
47 Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans. Eur J Nucl Med Mol Imaging 2002 1.30
48 Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003 1.28
49 Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother 2010 1.24
50 Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother 2002 1.15
51 Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes. J Immunother 2012 1.09
52 Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest 2002 1.05
53 Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Cancer Res 2012 1.05
54 Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial. Ann Surg Oncol 2014 1.03
55 An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc Natl Acad Sci U S A 2011 1.03
56 Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res 2004 1.02
57 Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. J Immunother 2006 1.00
58 Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor. J Immunother 2005 0.98
59 Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma. J Immunol Methods 2011 0.95
60 Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood 2013 0.94
61 Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma. Otolaryngol Head Neck Surg 2012 0.94
62 IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells. J Immunother 2009 0.92
63 Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine. J Immunother 2010 0.89
64 Characterization of a novel nonclassical T cell clone with broad reactivity against human renal cell carcinomas. J Immunol 2008 0.87
65 Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Ann Surg Oncol 2009 0.85
66 A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J Immunother 2004 0.83
67 Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells. Hum Gene Ther 2010 0.83
68 Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy. J Immunother 2011 0.82
69 Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer 2014 0.80
70 Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy. Clin Cancer Res 2013 0.80
71 Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research. Clin Adv Hematol Oncol 2003 0.79
72 Novel biochemistry: post-translational protein splicing and other lessons from the school of antigen processing. J Mol Med (Berl) 2005 0.75